Search results
Fusion Antibodies up 12% on cash runway relief
Proactive Financial News· 3 hours agoFusion Antibodies PLC (AIM:FAB) saw its shares rise by 12% after confirming it has a cash runway extending into the second quarter of 2025. Fusion,...
Covid wave feared as FLiRT variants spread and vaccine drive falters
Daily Mail· 2 days agoFootball fans gathering to watch the Euros this year could be behind the 'building' summer Covid...
Mammalian cell display with automated oligo design and library assembly allows for rapid residue...
Nature· 1 day agoUsing a new method for rapid, residue-level epitope determination combining flow cytometry and surface displayed alanine substitution variants the authors determined the epitopes of three new antibodies binding the SARS-CoV-2 Spike protein.
What to know about dengue as CDC warns of rising risk in US
CNN via Yahoo News UK· 6 days agoDengue virus is the most common mosquito-spread virus globally, but generally relatively rare in the...
FDA approves second Alzheimer’s drug that can modestly slow disease
Express and Star· 24 hours agoUS officials have approved another Alzheimer’s drug that can modestly slow the disease, providing a...
'World's most infectious disease' breakthrough could wipe it out for good
The Sun· 7 days agoA 'SIGNIFICANT' breakthrough in the battle to beat measles has been made by scientists developing...
Tackling Hard-To-Treat Tumors
Forbes· 1 day agoOne of the ways researchers are trying to address this problem is by disarming the tumor’s defenses against the immune system. This article describes one such effort: a novel antibody ...
A New Alzheimer’s Drug May Be the Most Effective One Yet
Time via Yahoo News UK· 17 hours agoDonanemab’s effectiveness likely comes from its ability to specifically target the toxic plaques of...
Vigil Neuroscience, Inc. (VIGL): Is This the Best Biotech Penny Stock to Buy Now?
Insider Monkey via Yahoo Finance UK· 4 days agoWe recently compiled a list of the 10 Best Biotech Penny Stocks to Buy Now. In this article, we are...
Nipocalimab pivotal Phase 3 trial demonstrates sustained disease control in FcRn class for a broad...
PharmiWeb· 3 days agoJanssen-Cilag International NV, a Johnson & Johnson company today announced positive results from the nipocalimab Phase 3 Vivacity-MG3 study in patients with generalised myasthenia gravis (gMG ...
